Why the study?
Cardiac chamber and size increase predicts morbidity and death, but no standardized technique exists for assessing and reporting cardiac chamber and size on frequently utilized non-ECG gated CT.
Does non-ECG-gated computed tomography accurately assess cardiac chamber size and predict cardiomyopathy compared to echocardiography in cancer patients?
Does non-ECG-gated computed tomography accurately assess cardiac chamber size and predict cardiomyopathy compared to echocardiography in cancer patients?
Routine non-ECG-gated chest CT provides reliable cardiac morphologic assessments comparable to echocardiography, allowing opportunistic detection of cardiomyopathy in cancer patients.
Answers are grounded in this paper and cite their sources.
Cross-sectional CT data on cardiac chamber sizing are hypothesis-generating; standardized techniques require prospective validation before clinical adoption.
Background: A number of cardiovascular processes have been linked to cardiac chamber and cardiac size increase as a significant biomarker for predicting morbidity and death. There is no standardized technique for assessing and reporting cardiac chamber and cardiac size, despite the fact that non-electrocardiographically (ECG) gated multidetector CT is a frequently utilized cross-sectional imaging modality to assess numerous cardiothoracic diseases . Patients and Methods :Our study encompassed 106 patients. All patients were diagnosed with primary cancer and underwent computed tomography (CT) for either initial evaluation or subsequent monitoring. Cardiac measurements were obtained in CT and compared to Echocardiographic results done within two months Results: left cardiac chamber measurements had good correlation with echocardiographic measurements with a P value of 0.021 in differentiating between maximum cardiac width in patient with impaired vs normal cardiac function. Conclusion: our study confirms that non–ECG-gated CT provides reliable cardiac morphologic assessment comparable to echocardiography especially to detect cardiomyopathy in patients during their cancer treatment follow up.
No takes yet. Share an insight, caveat, or question.
Beshir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: